Literature DB >> 12384385

Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro.

Denis Bugnon1, Eric Giannoni, Paul Majcherczyk, Michel P Glauser, Philippe Moreillon.   

Abstract

While developing a high-pressure liquid chromatography assay for cefepime in plasma, we observed significant drug degradation at 20 and 37 degrees C but not at 4 degrees C. This plasma-related degradation persisted after protein removal. This warrants caution regarding cefepime assays for pharmacokinetic and pharmacodynamic studies of cefepime in vitro and in vivo.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12384385      PMCID： PMC128753          DOI： 10.1128/AAC.46.11.3654-3656.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Effects of age and gender on pharmacokinetics of cefepime.

Authors:  R H Barbhaiya; C A Knupp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Authors:  R H Barbhaiya; S T Forgue; C R Gleason; C A Knupp; K A Pittman; D J Weidler; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.

Authors:  V P Shah; K K Midha; S Dighe; I J McGilveray; J P Skelly; A Yacobi; T Layloff; C T Viswanathan; C E Cook; R D McDowall
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Oct-Dec       Impact factor: 2.441

5.  High-performance liquid chromatographic assay for cefepime in serum.

Authors:  H Elkhaïli; L Linger; H Monteil; F Jehl
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-03-07

6.  High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Authors:  R H Barbhaiya; S T Forgue; W C Shyu; E A Papp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Determination of cefepime and cefpirome in human serum by high-performance liquid chromatography using an ultrafiltration for antibiotics serum extraction.

Authors:  D Breilh; C Lavallee; A Fratta; D Ducint; P Cony-Makhoul; M C Saux
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-10-29

8.  Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.

Authors:  J O Fubara; R E Notari
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

9.  Quantitative determination of cefepime in plasma and vitreous fluid by high-performance liquid chromatography.

Authors:  I N Valassis; M Parissi-Poulou; P Macheras
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-01-22

10.  N-oxidation of N-methylpyrrolidine released in vivo from cefepime.

Authors:  S T Forgue; P Kari; R Barbhaiya
Journal:  Drug Metab Dispos       Date:  1987 Nov-Dec       Impact factor: 3.922
View more
  8 in total

1.  Prospective determination of plasma imipenem concentrations in critically ill children.

Authors:  Eric Giannoni; Philippe Moreillon; Jacques Cotting; Adrien Moessinger; Jacques Bille; Laurent Décosterd; Giorgio Zanetti; Paul Majcherczyk; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.

Authors:  F Lamoth; T Buclin; A Pascual; S Vora; S Bolay; L A Decosterd; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

4.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

5.  Development and validation of a volumetric absorptive microsampling- liquid chromatography mass spectrometry method for the analysis of cefepime in human whole blood: Application to pediatric pharmacokinetic study.

Authors:  Ganesh S Moorthy; Christina Vedar; Nicole R Zane; Kevin J Downes; Janice L Prodell; Mary Ann DiLiberto; Athena F Zuppa
Journal:  J Pharm Biomed Anal       Date:  2019-11-20       Impact factor: 3.935

6.  A Population Pharmacokinetic Analysis to Study the Effect of Extracorporeal Membrane Oxygenation on Cefepime Disposition in Children.

Authors:  Athena F Zuppa; Nicole R Zane; Ganesh Moorthy; Heidi J Dalton; Alan Abraham; Ron W Reeder; Joseph A Carcillo; Andrew R Yates; Kathleen L Meert; Robert A Berg; Anil Sapru; Peter Mourani; Daniel A Notterman; J Michael Dean; Marc R Gastonguay
Journal:  Pediatr Crit Care Med       Date:  2019-01       Impact factor: 3.624

7.  Cefepime induced acute interstitial nephritis--a case report.

Authors:  Kathy Mac; Ruchir Chavada; Sharon Paull; Kenneth Howlin; Jeffrey Wong
Journal:  BMC Nephrol       Date:  2015-02-11       Impact factor: 2.388

8.  Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.

Authors:  Sonya C Tang Girdwood; Peter H Tang; Mark E Murphy; Andrea R Chamberlain; Laura A Benken; Rhonda L Jones; Erin M Stoneman; Jennifer M Kaplan; Alexander A Vinks
Journal:  J Clin Pharmacol       Date:  2020-10-27       Impact factor: 3.126
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.